Know Labs, Inc. (KNWN), a medical device company headquartered in Washington, announced on Wednesday that it is actively working to regain compliance and is appealing the New York Stock Exchange (NYSE)'s decision to delist its common stock. The company is presenting its case to the Listings Qualifications Panel.
During this period, trading of Know Labs' stock on the NYSE American will be suspended. NYSE Regulation has commenced proceedings to delist the company's stock due to it no longer fulfilling the listing requirements, specifically the bid price dropping below $0.10, as stipulated in Section 1003(f)(v) of the NYSE American Company Guide.
In the interim, as of January 29, the Financial Industry Regulatory Authority (FINRA)'s Department of Market Operations has allocated the symbol "KNWN" for the company's stock, which will now be quoted and traded on the over-the-counter (OTC) market.
At present, KNWN is trading at $0.072, reflecting a 44% increase, on the OTC Pink market.
